Drug intelligence / Profile preview

N-801

Development stage: Unknown
Lead developer: Dragonfly Therapeutics
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

N-801 is an investigational cancer immunotherapy drug described in the literature as a multi-cytokine fusion protein. It is designed to provide immunostimulatory interleukin signals to the tumor microenvironment by anchoring at the tumor site, thereby potentially enhancing anti-tumor immune responses. N-801 is not currently an FDA-approved or widely marketed product, and evidence suggests it remains in early (preclinical or clinical) phases of development.

Targets

IL-18R (Interleukin-18 receptor complex)IL-12R (Interleukin-12 receptor)IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on N-801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-801.

Explore the full profile